Besponsainotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datrowaydatopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Emrelistelisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Enhertufam-trastuzumab deruxtecan · HER2HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
Kadcylaado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarggemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcevenfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivypolatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Tivdaktisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Zynlontaloncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice